Zhang Financial LLC Trims Holdings in Pfizer Inc. (NYSE:PFE)

Zhang Financial LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,535 shares of the biopharmaceutical company’s stock after selling 3,648 shares during the period. Zhang Financial LLC’s holdings in Pfizer were worth $2,059,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Moneta Group Investment Advisors LLC lifted its position in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank acquired a new stake in shares of Pfizer in the fourth quarter valued at $3,150,472,000. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after buying an additional 9,393,992 shares in the last quarter. Morgan Stanley grew its stake in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock valued at $4,073,547,000 after buying an additional 7,419,929 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Pfizer in the first quarter valued at $311,238,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Price Performance

NYSE PFE traded up $0.49 during mid-day trading on Friday, hitting $25.88. The stock had a trading volume of 21,376,043 shares, compared to its average volume of 42,192,488. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The company has a market cap of $146.55 billion, a price-to-earnings ratio of 71.67, a P/E/G ratio of 1.15 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a 50 day simple moving average of $27.14 and a 200 day simple moving average of $28.74.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.